Bupropion/naltrexone fixed-dose combination for the treatment of obesity.
Drugs Today (Barc)
; 47(8): 575-81, 2011 Aug.
Article
em En
| MEDLINE
| ID: mdl-21850280
ABSTRACT
The combination of bupropion and naltrexone is one of the most promising new possibilities for the treatment of obesity in an era of increasing prevalence of this disease and decreasing options for its pharmacological management. Although approved by FDA panel members, it was temporally rejected by the FDA afterwards, who demanded more cardiovascular safety data for its commercialization. This monograph will focus on the physiology involved in its mechanisms of action and results of clinical trials.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Bupropiona
/
Naltrexona
/
Obesidade
Tipo de estudo:
Risk_factors_studies
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Drugs Today (Barc)
Assunto da revista:
MEDICINA OCUPACIONAL
/
SAUDE AMBIENTAL
Ano de publicação:
2011
Tipo de documento:
Article
País de afiliação:
Brasil